Profluent Raises $35M in Funding to Revolutionize Protein Design with AI, Aiming to Accelerate Biomedical Innovations
Profluent aims to revolutionize protein design with its AI-first approach.
Company Name: Profluent
Location: Berkeley, CA
Sector: Biotechnology/AI-First Protein Design
Funding Details: Raised $35M in funding led by Spark Capital, with participation from Insight Partners, Air Street Capital, and angel investors from prominent companies and institutions.
Purpose of Investment: To facilitate the creation and validation of innovative, functional proteins, aiming to advance healthcare and disease treatment solutions.
Leadership: CEO Ali Madani, Chief Business Officer Hilary Eaton, and VP and Head of Gene Editing Peter Cameron, PhD. The board includes Fraser Kelton, former Head of Product at OpenAI, and Nabeel Hyatt from Spark Capital.
Product: Profluent leverages AI to design and validate novel, functional proteins, initiating a shift from serendipitous discovery to intentional design in biomedicine. Focusing initially on CRISPR systems, the company seeks to expedite the development of vital genetic medicines through its cutting-edge deep generative models.
About Company: Profluent aims to revolutionize protein design with its AI-first approach. By optimizing across multiple functional attributes, Profluent’s technology has the potential to significantly impact the field of biomedicine, especially in the development of genetic medicines. The involvement of industry veterans and the focus on CRISPR technology underscore the company's ambitious vision for the future of healthcare.